National and Kapodistrian University of Athens
Διαγνωστική αξία των βιοδεικτων α-φετοπρωτεινης (AFP) και πρωτεΐνης επαγόμενης από την έλλειψη βιταμίνης Κ(PIVKA-II) για τη διάγνωση του ηπατοκυτταρικού καρκινώματος (ΗΚΚ) σε ασθενείς με κίρρωση ήπατος
Abstract
dc:descriptionABSTRACT Aim: The aim of the study was to evaluate the accuracy of serum biomarkers (AFP/PIVKA-II) and their combination in HCC diagnosis among Caucasian cirrhotic patients. Methods: We prospectively evaluated serum AFP and PIVKA-II levels in Caucasian patients with compensated or decompensated liver cirrhosis who consecutively presented with or without concomitant HCC in our department (6/2022-6/2024). The presence of cirrhosis was evaluated in the vast majority of patients using transient elastography and in a small proportion of patients liver biopsy was performed to define the diagnosis of cirrhosis. Cirrhotic patients of any etiology who declared alcohol use at the time or during the last 6 months of patient screening were excluded, as well as those taking vitamin K antagonist or other anticoagulants. All patients in whom HCC was suspected due to the presence of liver lesions in imaging subsequently underwent liver biopsy in order to histologically confirm HCC diagnosis. Results: Serum AFP/PIVKA-II levels were evaluated in 218 cirrhotics (163 males, 118 CTP-A, 66 ALBI-I, 111 with varices, 63 with diabetes) with (n=90, HCC group) or without (n=128, control group) HCC. Patients with HCC were categorized to BCLC stage 0/A (n=12), B (n=21), C (n=48) and D (n=9). The two groups were comparable for all baseline parameters except for age, platelets and diabetes presence. Median levels of AFP (239.1 vs 4.0 ng/mL) and PIVKA-II (4082.7 vs 45.8 mAU/ml) were both significantly higher in HCC group compared to controls (p<0.001). AUROC and cut-off value for HCC diagnosis were 88%/12.35 ng/ml (AFP) and 84.4%/677.13 mAU/ml (PIVKA-II), whereas their combination showed better diagnostic accuracy (AUROC=90.2%). The diagnostic accuracy of each biomarker separately was moderate or good in BCLC-0/A/B and was excellent only for BCLC-C patients (AFP: AUROC=94.3%, cut-off=12.35ng/ml and PIVKA-II: 91.3%, 253.51mAU/ml), whereas their combination presented acceptable results in BCLC-B (AUROC=92.4%) and BCLC-C (AUROC=95.7%) patients. Excluding HCC patients with high AFP (above 400 ng/ml), the diagnostic accuracy of each biomarker separately and their combination was moderate/good in all groups, except for their combination in BCLC-C (AUROC=90.5%). Conclusion: Each biomarker separately showed acceptable accuracy for detecting HCC in cirrhotic patients and excellent for those in BCLC-C stage. The combination of the biomarkers presented excellent results in BCLC-B/C patients. The diagnostic accuracy of PIVKA-II and the combination of the two biomarkers in patients expressing low / non-diagnostic AFP levels was good in BCLC-B and excellent in BCLC-C patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Syriha, Antonia
- Συρίχα, Αντωνία
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59964